Genetic variation in genes associated with arsenic metabolism: glutathione S-transferase omega 1-1 and purine nucleoside phosphorylase polymorphisms in European and indigenous Americans *.

Individual variability in human arsenic metabolism has been reported frequently in the literature. This variability could be an underlying determinant of individual susceptibility to arsenic-induced disease in humans. Recent analysis revealing familial aggregation of arsenic metabolic profiles suggests that genetic factors could underlie interindividual variation in arsenic metabolism. We screened two genes responsible for arsenic metabolism, human purine nucleoside phosphorylase (hNP), which functions as an arsenate reductase converting arsenate to arsenite, and human glutathione S-transferase omega 1-1 (hGSTO1-1), which functions as a monomethylarsonic acid (MMA) reductase, converting MMA(V) to MMA(III), to develop a comprehensive catalog of commonly occurring genetic polymorphisms in these genes. This catalog was generated by DNA sequencing of 22 individuals of European ancestry (EA) and 24 individuals of indigenous American (IA) ancestry. In hNP, 48 polymorphic sites were observed, including 6 that occurred in exons, of which 1 was nonsynonymous (G51S). One intronic polymorphism occurred in a known enhancer region. In hGSTO1-1, 33 polymorphisms were observed. Six polymorphisms occurred in exons, of which 4 were nonsynonymous. In contrast to hNP, in which the IA group was more polymorphic than the EA group, in hGSTO1-1 the EA group was more polymorphic than the IA group, which had only 1 polymorphism with a frequency > 10%. Populations representing genetic admixture between the EA and IA groups, such as Mexican Hispanics, could vary in the extent of polymorphism in these genes based upon the extent of admixture. These data provide a framework in which to conduct genetic association studies of these two genes in relevant populations, thereby allowing hNP and hGSTO1-1 to be evaluated as potential susceptibility genes in human arsenicism. Key words: arsenic, biotransformation, European ancestry, indigenous American ancestry, hGSTO1-1, hNP, polymorphisms, SNP. Environ Health Perspect 111:1421-1427 (2003). doi:10.1289/txg.6420 available via http://dx.doi.org/[Online 21 July 2003]

**********

Arsenic-induced human carcinogenesis remains one of the most perplexing mechanistic puzzles in contemporary toxicology. Although current animal models of arsenic-induced carcinogenesis are of equivocal biological relevance, convincing human epidemiologic data have identified the skin, lung, and bladder as targets of carcinogenesis caused by chronic exposure to arsenic (Bates et al. 1992). Several potential carcinogenic mechanisms have been proposed, including inhibition of DNA repair enzymes, tumor promoter-like induction of proliferation, alteration of DNA methylation, and clastogenesis (Kitchin 2001). Notwithstanding their lack of in vivo potency in carcinogenesis assays, arsenic compounds are potent toxicants both in vitro and in vivo. Biological effects of in vitro or in vivo exposure to arsenic include apoptosis, protein ubiquitination, cellular proliferation, oxidative stress, and enzyme inactivation (Asmuss et al. 2000; Chen et al. 2001; Hunter 2000; Kirkpatrick et al. 2003). Thus, arsenicals are clearly biologically active, but no definitive relationship has been established that links carcinogenesis to specific toxic endpoints.

Toxicologists have been able to assemble the key steps of the arsenic biotransformation pathway by identifying the chemical species of biotransformed arsenic. This pathway includes-several oxidation state changes, successive oxidative methylations, and at least four metabolites (Vahter 2002). Notwithstanding the lack of specifically identified carcinogenic mechanisms of action, available evidence suggests that arsenic biotransformation is likely to be key to arsenic-induced disease. First, experimental evidence suggests that arsenic metabolism in humans could produce toxic intermediates and certainly governs the in vivo balance between chemical arsenic species with high biological potency and those with low biological potency. Historically, methylation of arsenic has been regarded as a detoxification mechanism (Abernathy et al. 1999). Within that historical context, detoxification typically referred to the lower cytotoxic potency of methylated arsenicals, namely monomethylarsonic acid of valence V [MMA(V)] and dimethylarsinic acid of valence V [DMA(V)], compared with inorganic arsenic species. In addition to the differential cytotoxicity between inorganic arsenic and organic arsenic in the +V valence state, there is differential cytotoxicity between inorganic arsenic in the +III valence state and inorganic arsenic in the +V valence state. To complicate matters further, more recently, it has been shown that, as opposed to the low potency of MMA(V) and DMA(V), MMA(III) and DMA(III) are potent inducers of apoptosis, cytosolic protein binding, and epithelial hyperplasia (Thomas et al. 2001). In fact these methylated arsenic (III) compounds may be the most potent toxicants in the entire metabolic pathway. Although no direct link exists between arsenic-induced cytotoxicity and arsenic-induced carcinogenesis, the differential biological activity of arsenic metabolites is probably not restricted to cytotoxicity. Thus, understanding arsenic metabolism is likely to be key to a complete understanding of arsenic carcinogenesis.

A second, equally compelling reason to explore arsenic metabolism is the evidence that the metabolism of arsenic may be genetically influenced, with significant interindividual variation in arsenic metabolism among humans. Interspecies comparisons also suggest a genetic component to arsenic metabolism. Comparison of nine different strains of rats in which liver S9 fractions were exposed to inorganic arsenic revealed a 2-fold difference between the strain with the lowest rate of arsenic methylation versus the strain with the highest rate (Thomas et al. 2001). Parallel experiments corroborated the S9 fraction results with intact hepatocytes from the nine strains. In experiments examining the rate of formation of methylated arsenic in hepatocytes taken from different human donors, nearly a 10-fold difference was observed (Styblo et al. 1999). Although this difference could be due to conditions surrounding donor organ condition or assay conditions, it is interesting to note that a comparison of several large studies measuring the distribution of urinary arsenic metabolites in humans exposed to inorganic arsenic via drinking water demonstrated a nearly 7-fold difference in the fraction of urinary arsenic as MMA (Vahter 2000). It is likely that some of this variability is environmental; however, it is possible that genetic variation may underlie some of the variation in arsenic metabolism. A role for genetic determinants of arsenic biotransformation is supported in recent work by Chung et al. (2002), in which familial aggregation in the pattern of urinary methylated arsenic metabolites was demonstrated in Chilean families.

A prerequisite in the evaluation of potential genetic determinants of arsenic metabolism is the development of a comprehensive catalog of genetic variation in genes whose products are involved in arsenic biotransformation. With such a catalog, one can test individual or combinations of polymorphic sites for association with phenotypes related to arsenic biotransformation, such as patterns of urinary metabolites. This study represents the first systematic polymorphism screening of two genes involved in arsenic biotransformation, human purine nucleoside phosphorylase (hNP) and human glutathione S-transferase omega 1-1 (hGSTO1-1). The products of these genes function as arsenate reductase and MMA, As(V) reductase, respectively (Radabaugh et al. 2002; Zakharyan et al. 2001). Because a major focus of our laboratory is the local arsenic-affected population [European ancestry (EA) individuals and Mexican ancestry individuals], we developed this catalog using two populations of subjects, EA subjects and indigenous American ancestry (IA) subjects. Because Mexican ancestry individuals represent predominantly an admixture between Europeans and indigenous Americans, these two populations make up the primary genetic background of the locally relevant populations (Cerda-Flores et al. 2002)

Materials and Methods

Subjects

Anonymous DNA samples from healthy individuals of self-reported ancestry were obtained from the Coriell Institute (Camden, NJ). Twenty-two samples from individuals of EA and 24 samples from individuals of IA were studied. EA individuals were selected from unrelated Centre d'Etude du Polymorphism Humain samples. The geographical origin of the IA samples consisted of 5 samples from Peru, 9 samples from Mexico, 1 sample from Ecuador, and 9 samples from Brazil. One DNA sample isolated from chimpanzee was also included in the study. These samples are commercially available; individual sample identification and ordering information are shown in the Supplemental Material, Table 1.

Polymerase Chain Reaction

Genomic sequences for hNP and hGSTO1-1 were accessed from the UCSC Genome Browser (http://www.genome.ucsc.edu) November 2002 freeze. Polymerase chain reaction (PCR) amplicons were designed to completely traverse each gene, such that each amplicon was approximately 900 bp long, and consecutive amplicons overlapped each other by approximately 200 bp. PCR reactions contained 20 ng genomic DNA, 1 pmol of each primer, 0.2 U taq polymerase (platinum taq; Invitrogen, Carlsbad, CA) and 0.1 [micro]M deoxynucleotide triphosphates in a total volume of 10 [micro]L. Specific reaction conditions, including primer sequences, are available from the authors.

Direct Polymerase Chain Reaction Sequencing

PCR amplicons were prepared for cycle sequencing by diluting them with water, using a dilution range of 1:3-1:6, depending on the reaction yield determined by agarose gel electrophoresis. Cycle-sequencing reactions were assembled using 0.4 [micro]L cycle-sequencing premix (BigDye, version 3.0; Applied Biosystems, Foster, CA), 1 pmol sequencing primer, 1.8 [micro]L 5x sequencing dilution buffer and 5 [micro]L PCR product in a final volume of 10 [micro]L. Cycle-sequencing reactions were purified using DNA-affinity magnetic beads (Agencourt Biosciences, Beverly, MA). Purified sequencing reactions were electrophoretically analyzed using a DNA Analyzer 3730 (Applied Biosystems).

Polymorphism Identification and Analysis

Sequence chromatograms were processed for base calling and assembly using the phred, phrap, and Consed suite of software programs (Ewing et al. 1998; Gordon et al. 1998). Initial polymorphism tagging was performed using Polyphred, with a minimum sequence quality of phred 25 (Nickerson et al. 1997). Potential polymorphic sites initially identified by Polyphred were individually confirmed by visual inspection of sequence traces. A criterion of this visual inspection-confirmation was that the polymorphism must be observed in multiple chromatograms from singleton polymorphisms (polymorphisms occurring in only one subject) or in multiple subjects. For these confirmed polymorphic sites, each genotype for each subject was also confirmed by visual inspection of chromatograms. Polymorphic sites and associated subject-identified genotypes were automatically output to a relational database for further analysis, which included the automated generation of ethnicity-specific genotype frequencies, allele frequencies, and goodness-of-fit tests for Hardy-Weinberg equilibrium. Haplotypes were inferred using a Gibbs-sampling algorithm as implemented in the Phase software program (Stephens et al. 2001). Because the accuracy of statistically inferred haplotype increases with increasing haplotype frequency, we used polymorphisms with a minimum frequency [minor allele frequency (MAF)] of 0.10 to define relatively common haplotypes (Tishkoff et al. 2000). Pairwise linkage disequilibrium (LD) was calculated as [r.sup.2], a measure of the product-moment correlation coefficient (Devlin and Risch 1995).

Gene Context of Polymorphisms

Each gene was annotated graphically using the Artemis software program (Rutherford et al. 2000). Annotations included exon location, protein coding exon subset, reading frame, and polymorphism site. Coding region polymorphisms were evaluated for codon changes resulting from polymorphisms and the predicted effect on amino acid sequence.

Results

Glutathione S-Transferase Omega 1-1, MMA(V) Reductase

Based on mapping data from the November 2002 freeze of the Human Genome Browser, hGSTO1-1 contains six exons and extends for 12,551 bp of chromosome 10, in banding region q25.1. This is a region of low overall meiotic recombination, with a sex-averaged rate of 0.6 centimorgan (cM)/megabase (Mb) (Kong et al. 2002). The summary of the results of polymorphism screening in hGSTO1-1 is shown in Figure 1. Overall, 33 polymorphic sites were observed in the approximately 16,000 bases of genomic DNA that we sequenced, including the gene itself, 5' upstream, and 3' downstream genomic regions. The flanking sequences of all polymorphisms are given in Supplemental Material, Table 2, to allow unambiguous identification of polymorphisms. Complete genotypes for every individual at every site are shown in Supplemental Material, Figure 1 (EA population), and Supplemental Material, Figure 2 (IA population). Six polymorphisms occurred in exons 4 and 6, 2 of which were in the 3' untranslated region. The 4 remaining polymorphisms were nonsynonymous, resulting in two nonconservative amino acid substitutions (A140D, E208K), one amino acid deletion (E155del), and one conservative amino acid substitution (A236V). An interesting feature of these data is the distribution of polymorphisms between the EA and IA groups. Overall, the IA group was minimally polymorphic. The 14 polymorphisms observed in the IA population had a mean heterozygosity of 0.085 [+ or -] 0.064 (mean [+ or -] SD). In contrast, the mean heterozygosity of the 21 polymorphisms observed in the EA population was 0.223 [+ or -] 0.195. In large part the genetic polymorphisms of each group were exclusive to that group. We observed 19 polymorphisms exclusive to the EA group, 12 polymorphisms exclusive to the IA group, and only 2 shared polymorphisms (668 and 8283). LD among high-frequency (MAF > 0.10) polymorphisms was observed spanning over 11,000 bp in the EA group, with [r.sup.2] values approaching 1.0 between sites 2609 and 12707. Of the 8 polymorphisms in the EA group with MAF > 0.10, 7 (890, 1285, 2609, 6398, 8238, 10629, 12707) were in substantial LD with each other, with [r.sup.2] values between 0.60 and 1.0. LD in the IA group is difficult to evaluate because of the low frequency of the polymorphisms. Complete pairwise LD plots for hGSTO1-1 are shown in Supplemental Material, Figure 3 (EA group), and Supplemental Material, Figure 4 (IA group). The lack of diversity of the IA samples in this genomic region is also reflected in the haplotype analysis, shown in Tables 1 and 2. Considering only relatively common haplotypes, here arbitrarily defined as those composed of polymorphisms with an MAF > 0.10, only two haplotypes defined the entire IA population. These haplotypes, in turn, were defined by polymorphism 668, the only polymorphism that exceeded this MAF threshold. Thus, 84% of the chromosomes studied carried the major allele for polymorphism 668. The remaining 16% of the IA chromosomes carried the minor allele for polymorphism 668. Despite having 8 polymorphisms exceeding the 0.10 MAF threshold, the EA population was divided into only three primary haplotypes, which represented 93% of all EA chromosomes (Table 2). The most common EA haplotype, GGG + AACT, was also the common IA haplotype. The second most common EA haplotype, AAA - GCAC, was entirely absent from the IA population.

Purine Nucleoside Phosphorylase, Arsenate Reductase

hNP contains six exons and occupies 7,636 bp of chromosome 14 in band region q11.2. Substantially more meiotic recombination occurs in this region, compared with hGSTO1-1, with a sex-averaged rate of 3.7 cM/Mb (Kong et al. 2002). The summary of the results of polymorphism discovery in hNP is shown in Figure 2. The flanking sequences of all polymorphisms are given in Supplemental Material, Table 3, to allow unambiguous identification of polymorphisms. Complete genotypes for every individual at every site are shown in Supplemental Material, Figure 5 (EA population), and Supplemental Material, Figure 6 (IA population). Forty-eight polymorphisms were observed in the approximately 11,000 bases of DNA sequenced in this genomic region. Six polymorphisms occurred in exons, of which 1 (2544) occurred in the 5' untranslated RNA (UTR) and 1 (9987) in the 3' UTR. Of the remaining 4 polymorphisms, 3 (5483, 5594, 8254) were synonymous, and 1 (5574) resulted in a conservative amino acid substitution (G51S). In contrast to the situation for hGSTO1-1, in the genomic region of hNP, the IA group was more polymorphic than was the EA group, with mean heterozygosity values of 0.292 [+ or -] 0.127 for the IA group and 0.200 [+ or -] 0.132 for the EA group. Unlike hGSTO1-1, where 94% of the polymorphisms were exclusive to one group or the other, only 51% of all hNP polymorphisms were exclusive to one group, with 11 polymorphisms exclusive to the EA group and 13 polymorphisms exclusive to the IA group. Twenty-four polymorphisms were shared by both groups. The contrast in overall variability in the IA group between hGSTO1-1 and hNP was evident in the number of polymorphisms exceeding the 0.10 MAF threshold for haplotype analysis. In contrast to hGSTO1-1 (in which the IA group had 1 such polymorphism, whereas the EA group had 8), in hNP the IA group had 30 polymorphisms exceeding this threshold, whereas the EA group had only 19. LD in both the IA and EA groups was also more complex in hNP; in each group the high-frequency polymorphisms occurred in no less than three clusters, with high LD within a cluster but low LD between clusters (data not shown). Complete pairwise LD plots for hNP are shown in Supplemental Material, Figure 7 (EA group) and Supplemental Material, Figure 8 (IA group). The results of haplotype analysis for hNP are shown in Tables 3 and 4. Haplotype analysis revealed a greater complexity in the IA population within the hNP genomic region than in hGSTO1-1. Of the 48 IA chromosomes, 91.7% comprised five halotypes. Similarly, the EA population chromosomes could largely be described by five haplotypes, which accounted for 81.8% of all EA chromosomes studied.

Discussion

Genetic determinants of interindividual variability in arsenic metabolism have been speculated upon frequently in the literature, even before specific arsenic-metabolizing genes were identified (Abernathy et al. 1999; Vahter 1999, 2000). This project focused on a thorough screening of the first two characterized, arsenic-metabolic genes, with the objective of producing a catalog of commonly occurring polymorphisms in individuals of EA, IA, and by inference, many individuals of Mexican ancestry.

The genetics and molecular biology of hNP have been studied extensively because of the causative role of some nonsynonymous mutations in hNP in severe combined immunodeficiency syndrome (SCID) (Markert 1991; Sato and Wakabayashi 1998). Given the severe phenotype of SCID, it is not difficult to imagine that the spectrum of genetic variations one would observe in the general population would be confined to a limited range of functional changes in the protein. In fact for the 92 chromosomes that we studied, we observed only one nonsynonymous change in the predicted amino acid sequence, a conservative change of glycine to serine at residue 51. The 5 remaining polymorphisms that occurred in exons were either synonymous or positioned in untranslated mRNA regions. Although there is clear selection pressure against amino acid polymorphism in hNP, it is plausible that genetic polymorphism in gene regulatory regions could occur, as such changes could manifest themselves in a tissue-specific manner. Thus, in the presence of a polymorphism occurring in a gene regulatory region, a lethal target tissue such as T lymphocytes could be spared alterations in hNP gene expression, while a tissue critical to arsenic metabolism such as the liver could have altered transcriptional activity. Two polymorphisms, 3207 and 3253, are present within a region of intron 1 that has been defined as an enhancer element; this element may be absolutely necessary for gene transcription (Jonsson et al. 1992, 1994). No polymorphisms were observed in the minimal promoter elements that have been thus far defined for hNP (Jonsson et al. 1991).

hGSTO1-1 is a member of an atypical class of glutathione transferases, with a biochemical activity more closely resembling glutaredoxins than other, more typical, glutathione transferase enzymes (Board et al. 2000). Its involvement in biochemical pathways in the human remains to be fully characterized, but in addition to its involvement in arsenic biotransformation, hGSTO1-1 may include posttranslational processing of interleukin- 1[beta] (Laliberte et al. 2003). It is strongly expressed in several tissues, including colon, heart, liver, ovary, pancreas, prostate, and spleen (Yin et al. 2001).

Our analysis of hGSTO1-1 revealed a higher degree of predicted amino acid polymorphism than we observed in hNP. As opposed to hNP, in which only 17% of polymorphisms occurring in exons were nonsynonymous, 67% (4 of 6) of exon polymorphisms in hGSTO1-1 were nonsynonymous. Of these 4 nonsynonymous polymorphisms, 3 were predicted to result in nonconservative amino acid substitutions. Only one of these nonconservative substitutions occurred at above 0.10 MAF, 10629 (A140D), which occurred at 0.34 MAF in the EA population only. Because the minimal regulatory region of hGSTO1-1 has not yet been characterized, we cannot speculate as to which polymorphisms could be occurring in regulatory regions. Notwithstanding the amino acid diversity, perhaps the most notable features of the genetic evaluation of hGSTO1-1 are the striking lack of polymorphism in the IA group and the low complexity of the EA group. One high-frequency polymorphism, 668, is common to both the IA group and the EA group. Because the IA group probably derives from Asia, the appearance of this polymorphism in both these geographically diverse groups suggests that this may be an ancient polymorphism. Aside from polymorphism 668, the IA group is monomorphic with respect to polymorphisms above a 0.10 MAF. The EA group has 7 additional polymorphisms above this MAF threshold, but they are all in a high degree of LD. This linked cluster of polymorphisms includes 1 nonsynonymous polymorphism, 10629. Thus, for the IA group, only 1 polymorphism, 668, is necessary to define all common haplotypes. In the EA group, only 2 polymorphisms, 668 and 1 polymorphism from the cluster of 7 linked polymorphisms, are necessary to define all of the common haplotypes. Several factors may explain the difference in overall variation in hGSTO1-1 between the IA and EA groups, including demographic events or, alternatively, selection pressure on this genomic region. Perhaps of greater significance is that for Mexican individuals that are some admixture between EA and IA, the extent to which an individual might be polymorphic for hGSTO1-1 is related to the degree of European admixture in his/her ancestry. Thus, genetic association studies of hGSTO1-1 in Mexican Hispanics should be carefully controlled for potential confounding by admixture.

To date, two studies have evaluated polymorphisms in hGSTO1-1. Tanaka-Kagawa et al. (2003), using polymorphism data from the Single Nucleotide Polymorphism database (dbSNP; http://www.ncbi.nlm.nih.gov/SNP/) studied 2 polymorphisms that were predicted to result in nonsynonymous changes, A140D and T217N. Substrate-dependent alterations in the resultant polymorphic proteins were observed. No validation of the presence or frequency of these 2 polymorphisms in human subjects was performed. Recently, Whitbread et al (2003). reported functional characterization of hGSTO1-1, together with polymorphism screening and validation in human subjects of three ancestries, African, Australian (EA), and Chinese. The authors based their polymorphism screening on existing polymorphisms in several databases. Through successive tiers of validation, only 1 of 26 hGSTO1-1 polymorphisms originally found in the databases was observed to occur in any of the three ethnic groups. This polymorphism resulted in a predicted nonsynonymous amino acid substitution, A140D. In the course of the study, the authors also discovered an insertion/deletion polymorphism that caused a deletion of residue E155 (E155del). Finally, the authors generated expression constructs for the three observed haplotypes of these two polymorphisms and assayed the resultant in vitro expressed protein function in enzymatic assays. Their functional analysis demonstrated altered thiol transferase and glutathione conjugation for the Al40, E155del haplotype. Our study also identified A140D (10629) and E155del (10674), and we discovered 1 additional nonsynonymous polymorphism in EA subjects, E208K (14902), and 1 in IA subjects, A236V (14987). The Whitbread study (Whitbread et al. 2003) illustrates two commonly encountered limitations of in silico-based polymorphism screening, namely, lack of validation of database polymorphisms and incomplete characterization of the gamut of commonly occurring polymorphisms in the population. In this regard, it is important to note that, of our 22 EA subjects, the same two subjects that were heterozygous for E155del, were also heterozygous for E208K. Thus, it is possible that these 2 polymorphisms are in substantial LD in EA subjects. As a result, it is possible that, by testing the 155 deletion, in the absence of the linked E208K substitution (an A140, E155del protein vs. an A140, E155del, E208K protein) the expression constructs in the Whitbread study do not accurately represent the commonly encountered hGSTO1-1 proteins, at least in their EA Australian group. This is particularly significant in light of the nature of the predicted E208K substitution, in which an acidic amino acid is substituted by a basic amino acid. Further testing is necessary to determine if these polymorphisms occur together in other ethnic groups.

Along with the EA and IA groups, we sequenced both hNP and hGSTO1-1 in one chimpanzee DNA sample (data not shown). Chimpanzees, the closest nonextinct primate relative of humans, do not biotransform arsenic into methylated species but do demonstrate arsenate reductase activity (Vahter et al. 1995; Wildfang et al. 2001). Thus, it was not surprising that we observed a high degree of protein homology between humans and chimpanzees in hNP and hGSTO1-1, with only one amino acid difference between human and chimpanzee hGSTO1-1, a conservative substitution of isoleucine (human) for valine (chimp) at residue 26. Two amino acid differences were observed in hNP. At residue 51, a site where we observed a glycine to serine nonsynonymous polymorphism in the human subjects, the chimp DNA sequence predicted a serine residue. At residue 277, all of our subjects were predicted to code for isoleucine, whereas the chimp coded for valine.

These data provide a functionally annotated catalog of commonly occurring genetic polymorphisms, in both protein coding and potential gene regulatory regions, in two important xenobiotic-metabolizing genes in populations that make up the genetic background of a substantial portion of Europe and the Americas. The combination of functional polymorphisms, clusters of linked polymorphisms, and haplotypes provide an essential framework from which to design genetic association studies to test key phenotypes related to arsenic biotransformation, such as urinary arsenic metabolic profile and susceptibility to arsenic-induced disease.

Table 1. hGST01-1 haplotypes: IA population.

Chromosomes (%)    Haplotype ID    668

84.1                    1           G
15.9                    2           A

Table 2. hGST01-1 haplotypes: EA population.

Chromosomes (%)    Haplotype ID    668    890    1285    2609    6398

47.7                    3           G      G      G       +       A
34.1                    4           A      A      A       -       G
11.4                    5           A      G      G       +       A

Chromosomes (%)    8238    10629    12707

47.7                A        C        T
34.1                C        A        C
11.4                A        C        T

Table 3. hNP haplotypes: IA population,

Chromosomes (%)    Haplotype ID    1014    1088    1095    1748    3207

33.3                    1           A       A       A       -       A
16.7                    2           G       T       A       -       A
14.6                    3           G       A       G       +       C
14.6                    4           A       A       A       -       A
12.5                    5           G       T       A       -       A

Chromosomes (%)    3679    4557    5328    5483    5574    5594    5802

33.3                -       G       T       C       G       C       A
16.7                +       T       G       C       A       T       G
14.6                -       T       T       T       A       T       G
14.6                -       G       T       C       G       C       A
12.5                -       G       T       C       G       C       A

Chromosomes (%)    6037    6272    6386    6586    6688    6986    7036

33.3                A       -       T       A       A       G       T
16.7                G       +       A       A       G       G       T
14.6                A       +       A       G       A       A       C
14.6                A       -       T       A       A       G       T
12.5                A       -       T       A       A       G       T

Chromosomes (%)    7424    7717    8477    8845    8883    8912    9400

33.3                T       A       T       C       G       C       G
16.7                T       A       A       T       C       C       G
14.6                G       G       A       C       G       T       G
14.6                T       A       T       C       G       C       G
12.5                T       A       T       C       G       C       A

Chromosomes (%)    9987    10328    10461    10544

33.3                C        C        C        G
16.7                C        T        C        A
14.6                C        C        C        G
14.6                C        C        T        G
12.5                T        C        C        G

Table 4. hNP haplotypes: EA population.

Chromosomes (%)    Haplotype ID    1014    1088    1095    1748    3207

47.7                     6          A       A       A       -       A
 9.1                     7          A       A       A       -       A
 9.1                     8          G       T       A       -       A
 9.1                     9          G       A       G       +       A
 6.8                    10          G       T       A       -       C

Chromosomes (%)    4557    5483    5574    5594    5802    6272    6386

47.7                G       C       G       C       A       -       T
 9.1                G       C       G       C       A       -       A
 9.1                G       C       G       C       A       -       T
 9.1                T       T       G       C       A       -       T
 6.8                G       C       A       T       G       +       A

Chromosomes (%)    6586    7036    7424    7717    8477    9400    9987

47.7                A       T       T       A       T       G       C
 9.1                G       C       G       G       A       G       C
 9.1                A       T       T       A       T       A       T
 9.1                G       C       G       G       A       G       C
 6.8                A       T       T       A       T       A       T

Figure 1. Summary of frequency and gene context of polymorphisms
discovered in hGST01-1 in EA (Europe) and IA (America) subjects. "ID"
column indicates the polymorphism identification number relative to the
location in the consensus sequence, with the first base of the
consensus numbered 1. * Indicates insertion/deletion. "ATG offset"
indicates the polymorphism location relative to the first base "A" of
the ATG methionine initiation codon. "Freq %" is the MAF, graphically
displayed in the column to the right. Nonsynonymous SNPs are denoted
by amino acid substitutions, e.g., A140D.

                                        Minor allele frequency

                                           European ancestry
            ATG
  ID       Offset    Gene context       Freq %    0.25    0.50

  668      -1859     5' Genomic           45
  890      -1637     5' Genomic           33
 1218      -1309     5' Genomic            0
 1285      -1242     5' Genomic           36
 1724       -803     5' Genomic            2
 1817       -710     5' Genomic            0
 2075       -452     5' Genomic            0
 2207       -320     5' Genomic            9
 2307       -220     5' Genomic            2
 2609 *       82     Intron 1             34
 6198       3671     Intron 2              0
 6398       3871     Intron 2             34
 7062       4535     Intron 2              0
 7688       5161     Intron 3              2
 7964       5437     Intron 3              0
 8238       5711     Intron 3             43
 8592       6065     Intron 3              2
 8963       6436     Intron 3              0
 9173       6646     Intron 3              9
 9963       7436     Intron 3              0
 9992       7465     Intron 3              0
10031       7504     Intron 3              2
10629       8102     Exon 4: A140D        34
10674 *     8147     Exon 4: E155del       5
10703       8176     Intron 5              2
10709       8182     Intron 5              7
11227       8700     Intron 5              0
12707      10180     Intron 5             33
13230      10703     Intron 5              2
14902      12375     Exon 6: E208K         5
14987      12460     Exon 6: A236V         0
15029      12502     Exon 6: 3' UTR        2
15035      12508     Exon 6: 3' UTR        0

           Minor allele frequency

             American ancestry

  ID       Freq %    0.25    0.50

  668        16
  890         0
 1218         4
 1285         0
 1724         0
 1817         4
 2075         2
 2207         0
 2307         0
 2609 *       0
 6198         2
 6398         0
 7062         4
 7688         0
 7964         2
 8238         4
 8592         0
 8963         2
 9173         0
 9963         2
 9992         4
10031         0
10629         0
10674 *       0
10703         0
10709         0
11227         5
12707         0
13230         0
14902         0
14987         4
15029         0
15035         8

Figure 2. Summary of frequency and functional context of polymorphisms
discovered in hNP in EA and IA subjects. Syn, synonymous SNP. "ID"
indicates the polymorphism identification number relative to the
location in the consensus sequence, with the first base of the
consensus numbered 1. * Indicates insertion/deletion. "ATG offset"
indicates the polymorphism location relative to the first base "A" of
the ATG methionine initiation codon. "Freq %" is the MAF, graphically
displayed in the column to the right. Nonsynonymous SNP are denoted by
amino acid substitutions, e.g., G51S.

                                       Minor allele frequency

                                          European ancestry
            ATG        Functional
  ID       offset       context        Freq %    0.25    0.50

  208      -2432     5' Genomic           2
  680      -1960     5' Genomic           2
 1014      -1626     5' Genomic          34
 1088      -1552     5' Genomic          14
 1095      -1545     5' Genomic          16
 1671       -969     5' Genomic           7
 1748 *     -892     5' Genomic          20
 2368       -272     5' Genomic           7
 2544        -96     Exon1: 5' UTR        2
 3207        567     Intron 1            18
 3253        613     Intron 1             0
 3679 *     1039     Intron 1             0
 4008       1368     Intron 1             2
 4303       1663     Intron 1            20
 4557       1917     Intron 1            20
 4594       1954     Intron 1             2
 5328       2688     Intron 1             0
 5483       2843     Exon: 2: Syn        14
 5574       2934     Exon: 2: G51S       14
 5594       2954     Exon: 2: Syn        14
 5703       3063     Intron 2             2
 5766       3126     Intron 2             2
 5802       3162     Intron 2            14
 6037       3397     Intron 2             2
 6272 *     3632     Intron 2            16
 6386       3746     Intron 2            25
 6563       3923     Intron 2             2
 6586       3946     Intron 2            24
 6631       3991     Intron 2             0
 6688       4048     Intron 2             0
 6938       4298     Intron 2             2
 6986       4346     Intron 2             5
 7036       4396     Intron 2            21
 7424       4784     Intron 2            25
 7717       5077     Intron 2            23
 8254       5614     Exon 5: Syn          0
 8477       5837     Intron 5            23
 8506       5866     Intron 5             0
 8538       5898     Intron 5             0
 8845       6205     Intron 5             0
 8883       6243     Intron 5             0
 8912       6272     Intron 5             0
 9293       6653     Intron 5             7
 9400       6760     Intron 5            16
 9987       7347     Exon 6: 3' UTR      16
10328       7688     3' Genomic           2
10461       7821     3' Genomic           0
10544       7904     3' Genomic           0

           Minor allele frequency

              American ancestry

  ID       Freq %    0.25    0.50

  208         0
  680         0
 1014        48
 1088        31
 1095        12
 1671         0
 1748 *      15
 2368         0
 2544         0
 3207        15
 3253         2
 3679 *      19
 4008         0
 4303        26
 4557        31
 4594         0
 5328        21
 5483        15
 5574        35
 5594        35
 5703         0
 5766         0
 5802        34
 6037        21
 6272 *      35
 6386        35
 6563         8
 6586        15
 6631         2
 6688         2
 6938         0
 6986        15
 7036        15
 7424        15
 7717        15
 8254         2
 8477        38
 8506         6
 8538         6
 8845        23
 8883        23
 8912        15
 9293         0
 9400        15
 9987        15
10328        23
10461        15
10544        23

REFERENCES

Abernathy CO, Liu YP, Longfellow D, Aposhian HV, Beck B, Fowler B, et al. 1999. Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect 107(7):593-597.

Asmuss M, Mullenders LH, Hartwig A. 2000. Interference by toxic metal compounds with isolated zinc finger DNA repair proteins. Toxicol Lett 112-113:227-231.

Bates MN, Smith AH, Hopenhayn-Rich C. 1992. Arsenic ingestion and internal cancers: a review. Am J Epidemiol 135(5):462-476.

Board PG, Coggan M, Chelvanayagam G, Easteal S, Jermiin LS, Schulte GK, et al. 2000. Identification, characterization, and crystal structure of the Omega class glutathione transferases. J Biol Chem 275(32):24798-24806.

Cerda-Flores RM, Villalobos-Torres MC, Barrera-Saldana HA, Cortes-Prieto LM, Barajas LO, Rivas F, et al. 2002. Genetic admixture in three Mexican Mestizo populations based on D1S80 and HLA-DQA1 loci. Am J Hum Biol 14(2):257-263.

Chen F, Vallyathan V, Castranova V, Shi X. 2001. Cell apoptosis induced by carcinogenic metals. Mol Cell Biochem 222(1-2):183-188.

Chung JS, Kalman DA, Moore LE, Kosnett MJ, Arroyo AP, Beeris M, et al. 2002. Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ Health Perspect 110(7):729-733.

Devlin B, Risch N. 1995. A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics 29(2):311-322.

Ewing B, Hillier L, Wendl MC, Green P. 1998. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 8(3):175-185.

Gordon D, Abajian C, Green P. 1998. Consed: a graphical tool for sequence finishing. Genome Res 8(3):195-202.

Hunter ES III. 2000. Role of oxidative damage in arsenic-induced teratogenesis. Teratology 62(4):240.

Jonsson JJ, Converse A, McIvor RS. 1994. An enhancer in the first intron of the human purine nucleoside phosphorytase-encoding gene. Gene 140(2):187-193.

Jonsson JJ, Foresman MD, Wilson N, McIvor RS. 1992. Intron requirement for expression of the human purine nucleoside phosphorylase gene. Nucleic Acids Res 20(12):3191-3198.

Jonsson JJ, Williams SR, McIvor RS. 1991. Sequence and functional characterization of the human purina nucleoside phosphorylase promoter. Nucleic Acids Res 19(18):5015-5020.

Kirkpatrick DS, Dale KV, Catania JM, Gandolfi AJ. 2003. Low-level arsenite causes accumulation of ubiquitinated proteins in rabbit renal cortical slices and HEK293 cells. Toxicol Appl Pharmacol 186(2):101-109.

Kitchin KT. 2001. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172(3):249-261.

Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, Richardsson B, et al. 2002. A high-resolution recombination map of the human genome. Nat Genet 31(3):241-247.

Laliberte RE, Perregaux DG, Hoth LR, Rosner PJ, Jordan CK, Peese KM, et al. 2003. Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processing. J Biol Chem 278(19): 16567-16578.

Markert ML 1991. Purina nucleoside phosphorylase deficiency. Immunodefic Rev 3(1):45-81.

Nickerson DA, Tobe VO, Taylor SL. 1997. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 25(14):2745-2751.

Radabaugh TR, Sampayo-Reyes A, Zakharyan RA, Aposhian HV. 2002. Arsenate reductase II. Purine nucleoside phosphorytase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem Res Toxicol 15(5):692-698.

Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, Rajandream MA, et al. 2000. Artemis: sequence visualization and annotation. Bioinformatics 16(10):944-945.

Sato T, Wakabayashi Y. 1998. [PNP deficiency]. Ryoikibetsu Shokogun Shirizu (21 pt 2):228-231.

Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68(4):978-989.

Styblo M, Del Razo LM, LeCluyse EL, Hamilton GA, Wang C, Cullen WR, et al. 1999. Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem Res Toxicol 12(7):560-565.

Tanaka-Kagawa T, Jinno H, Hasegawa T, Makino Y, Seko Y, Hanioka N, et al. 2003. Functional characterization of two variant human GSTO 1-1s (Ala140Asp and Thr217Asn). Biochem Biophys Res Commun 301(2):516-520.

Thomas DJ, Styblo M, Lin S. 2001. The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176(2):127-144.

Tishkoff SA, Pakstis AJ, Ruano G, Kidd KK. 2000. The accuracy of statistical methods for estimation of haplotype frequencies: an example from the CD4 locus. Am J Hum Genet 67(2):518-522.

Vahter M. 1999. Methylation of inorganic arsenic in different mammalian species and population groups. Sci Prog 82 (Pt 1):69-88.

--. 2000. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett 112-113:209-217.

--. 2002. Mechanisms of arsenic biotransformation. Toxicology 181-182:211-217.

Vahter M, Couch R, Nermell B, Nilsson R. 1995. Lack of methylation of inorganic arsenic in the chimpanzee. Toxicol Appl Pharmacol 133(2):262-268.

Whitbread AK, Tetlow N, Eyre HJ, Sutherland GR, Board PG. 2003. Characterization of the human Omega class glutathione transferase genes and associated polymorphisms. Pharmacogenetics 13(3):131-144.

Wildfang E, Radabaugh TR, Vasken Aposhian H. 2001. Enzymatic methylation of arsenic compounds. IX. Liver arsenite methyttransferase and arsenate reductase activities in primates. Toxicology 168(3):213-221.

Yin ZL, Dahlstrom JE, Le Couteur DC, Board PG. 2001. Immunohistochemistry of omega class glutathione S-transferase in human tissues. J Histochem Cytochem 49(8):983-987.

Zakharyan RA, Sampayo-Reyes A, Healy SM, Tsaprailis G, Board PG, Liebler DC, et al. 2001. Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem Res Toxicol 14(8):1051-1057.

Lizhi Yu, (1) Kelly Kalla, (1) Erin Guthrie, (1) Amy Vidrine, (1) and Walter T. Klimecki (1,2)

(1) Arizona Respiratory Center, Tucson, Arizona, USA; (2) Southwest Environmental Sciences Center, Tucson, Arizona, USA

Address correspondence to W.T. Klimecki, Arizona Health Sciences Center, BRL-Room C112, 1609 N. Warren Ave., Tucson, AZ 85724 USA. Telephone: [phone]. Fax: [phone]. E-mail: [e-mail]

* The online version of this article (available at http://www.ehponline.org) contains Supplemental Material.

This work was supported by National Institute for Environmental Health Sciences grant ES06694. WTK was also supported by National Heart, Lung, and Blood Institute grants HL66801, HL66806, and HL67672.

The authors declare they have no conflict of interest.

Received 21 April 2003; accepted 14 July 2003.